Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib vs Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 2)
NCT04338061Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Jul 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of evobrutinib in multiple sclerosis (MS), sponsored by Merck KGaA. Started Jul 2020; status: terminated.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04338061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338061.